NCT00647868View on ClinicalTrials.gov

NASOBOL in Hypogonadal Men in Comparison to Testosterone Levels in Normal Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Hypogonadism
Interventions
DRUG

testosterone

Intranasal testosterone, 7.6 mg (3.8 mg in each nostril) per application

Trial Locations (1)

90509

Harbor - UCLA Medical Center, Torrance

Sponsors
All Listed Sponsors
lead

Acerus Pharmaceuticals Corporation

INDUSTRY

NCT00647868 - NASOBOL in Hypogonadal Men in Comparison to Testosterone Levels in Normal Healthy Male Volunteers | Biotech Hunter | Biotech Hunter